Leerink Swann reiterated their outperform rating on shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in a research note published on Saturday. They currently have a $17.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $18.00. Leerink Swann also issued estimates for Amicus Therapeutics’ Q3 2017 earnings at ($0.30) EPS, Q4 2017 earnings at ($0.30) EPS, FY2017 earnings at ($1.31) EPS, FY2018 earnings at ($1.06) EPS, FY2019 earnings at ($0.78) EPS and FY2020 earnings at ($0.55) EPS.

FOLD has been the topic of a number of other research reports. BidaskClub lowered Amicus Therapeutics from a strong-buy rating to a buy rating in a research note on Wednesday, August 2nd. Zacks Investment Research lowered Amicus Therapeutics from a hold rating to a sell rating in a research note on Wednesday, July 12th. Bank of America Corporation lowered their price objective on Amicus Therapeutics from $10.00 to $9.00 and set a buy rating on the stock in a research note on Thursday, May 25th. Cowen and Company restated a buy rating and set a $16.00 price objective (up previously from $10.00) on shares of Amicus Therapeutics in a research note on Tuesday, July 11th. Finally, Robert W. Baird restated an outperform rating and set a $12.00 price objective on shares of Amicus Therapeutics in a research note on Friday, June 30th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $15.08.

Amicus Therapeutics (FOLD) traded up 3.43% during mid-day trading on Friday, hitting $13.88. The stock had a trading volume of 10,928,293 shares. The firm’s market capitalization is $2.28 billion. Amicus Therapeutics has a one year low of $4.41 and a one year high of $14.37. The stock’s 50 day moving average price is $13.20 and its 200 day moving average price is $9.77.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.03. The company had revenue of $7.16 million for the quarter, compared to analyst estimates of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same quarter last year, the company earned ($0.40) earnings per share. Analysts forecast that Amicus Therapeutics will post ($1.37) EPS for the current year.

WARNING: “Amicus Therapeutics, Inc. (FOLD) Given “Outperform” Rating at Leerink Swann” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/amicus-therapeutics-inc-fold-given-outperform-rating-at-leerink-swann/1568801.html.

In related news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the stock in a transaction on Thursday, July 13th. The shares were purchased at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jay Barth sold 30,000 shares of the firm’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $10.00, for a total value of $300,000.00. Following the transaction, the insider now owns 64,184 shares in the company, valued at approximately $641,840. The disclosure for this sale can be found here. 3.40% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Bank of Nova Scotia acquired a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at $1,944,000. Redmile Group LLC boosted its holdings in shares of Amicus Therapeutics by 5.9% in the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after purchasing an additional 668,080 shares in the last quarter. State Street Corp boosted its holdings in shares of Amicus Therapeutics by 2.2% in the 2nd quarter. State Street Corp now owns 5,892,564 shares of the biopharmaceutical company’s stock valued at $59,332,000 after purchasing an additional 125,635 shares in the last quarter. Gotham Asset Management LLC acquired a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at $308,000. Finally, Palo Alto Investors LLC boosted its holdings in shares of Amicus Therapeutics by 0.7% in the 2nd quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after purchasing an additional 57,800 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.